1 / 4

Kaplan-Meier Curve of Time to Primary End Point

0. 6. 12. 24. 30. 36. 18. Kaplan-Meier Curve of Time to Primary End Point. Pioglitazone (514 events) Placebo (572 events). Proportion of Events (%). HR = 0.90 (95% CI 0.80-1.02) p = 0.095. Time from Randomization (months). No. at Risk. Pioglitazone Placebo. 2488 2530. 2373 2413.

hilda
Download Presentation

Kaplan-Meier Curve of Time to Primary End Point

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 0 6 12 24 30 36 18 Kaplan-Meier Curve of Time to Primary End Point Pioglitazone (514 events) Placebo (572 events) Proportion of Events (%) HR = 0.90 (95% CI 0.80-1.02)p = 0.095 Time from Randomization (months) No. at Risk Pioglitazone Placebo 2488 2530 2373 2413 2302 2317 2218 2215 2146 2122 348 345 PROactive investigators. Lancet 2005;366:1279-1289.

  2. 0 6 12 24 30 36 18 Kaplan-Meier Curve of Time to Secondary End Point Pioglitazone (301 events) Placebo (358 events) Proportion of Events (%) HR = 0.84 (95% CI 0.72-0.98)p = 0.027 Time from Randomization (months) No. at Risk Pioglitazone Placebo 2536 2566 2487 2504 2435 2442 2381 2371 2336 2315 396 390 PROactive investigators. Lancet 2005;366:1279-1289.

  3. Change in Posterior-Wall Mean CIMT Glimepiride Pioglitazone LS Mean Change from Baseline, mm Baseline 24 48 72 Week No. of Observations Glimepiride Pioglitazone 186 175 170 166 186 175 186 175 Mazzone T et al. JAMA 2006;296:2572-2581.

  4. Change in Posterior-Wall Maximum CIMT Glimepiride Pioglitazone LS Mean Change from Baseline, mm Baseline 24 48 72 Week No. of Observations Glimepiride Pioglitazone 186 175 170 166 186 175 186 175 Mazzone T et al. JAMA 2006;296:2572-2581.

More Related